Trials / Recruiting
RecruitingNCT05959694
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
A Phase Ib/II Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory CLL/SLL.
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 107 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3909 tablet | TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. |
Timeline
- Start date
- 2023-10-11
- Primary completion
- 2025-12-01
- Completion
- 2026-06-01
- First posted
- 2023-07-25
- Last updated
- 2023-10-23
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05959694. Inclusion in this directory is not an endorsement.